| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6175891 | European Urology | 2016 | 7 Pages |
Abstract
More than 800 mRCC patients received sunitinib for between 2 and 6 yr without experiencing new or more severe treatment-related toxicity. Clinicians may be able to prescribe chronic sunitinib treatment for as long as patients continue to derive clinical benefit, without untoward additional risk.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Camillo Porta, Martin E. Gore, Brian I. Rini, Bernard Escudier, Subramanian Hariharan, Lorna P. Charles, Liqiang Yang, Liza DeAnnuntis, Robert J. Motzer,